What Vividion Therapeutics does

Vividion Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class covalent small molecule therapeutics against disease-causing proteins historically considered undruggable. The company was founded in 2016 based on foundational research from Scripps Research scientists Ben Cravatt, Phil Baran, and Jin-Quan Yu, and was acquired by Bayer AG in August 2021 for approximately $2 billion, becoming a wholly-owned and independently operated subsidiary headquartered in San Diego, California.

Vividion's core asset is a proprietary chemoproteomics discovery platform that combines a custom covalent fragment library of over 50,000 small molecules, high-resolution high-throughput mass spectrometry screening against thousands of proteins in their native cellular state, and an integrated data portal that overlays approximately 250,000 new data points per day with public human genetics and structural biology resources. The platform has produced three clinical-stage programs: VVD-214 (covalent allosteric WRN helicase inhibitor for MSI-high solid tumors, Phase Ib), VVD-037 (first-in-class KEAP1 activator for NRF2-activated cancers, Phase I), and VVD-642 (RAS-PIK3CA interaction inhibitor for RAS-driven cancers, Phase I), plus undisclosed early-stage immunology programs. Recent platform publications have appeared in Journal of Medicinal Chemistry and Science.

Vividion is pre-revenue with no commercialized products; pricing for investigational drugs is not publicly disclosed. The company is funded entirely through Bayer as its parent company and leverages Bayer's global clinical development infrastructure (current Phase Ib trial enrolls across 11 countries) and commercial capabilities for eventual product launch. The go-to-market model is effectively enterprise partnership via Bayer rather than independent commercialization, and clinical operations function through Bayer's clinical trial site network globally. Headcount of 251–500 employees supports a maturing clinical-stage organization spanning discovery, translational research, CMC, and clinical development.

Name

Vividion Therapeutics

Legal name

Vividion Therapeutics, Inc.

Website

https://vividion.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

Vividion Therapeutics is a clinical-stage biopharmaceutical company and Bayer AG subsidiary that uses a proprietary chemoproteomics platform to develop covalent small molecule therapeutics against previously undruggable proteins in oncology and immunology. It has three Phase I clinical programs—VVD-214 (WRN), VVD-037 (KEAP1), and VVD-642 (RAS-PIK3CA)—and is pre-revenue.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Small molecule therapeutics
• Chemoproteomics drug discovery
• Covalent inhibitor development
• Oncology drug discovery
• Precision medicine development

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

1. Pharmaceutical Product Revenue: Vividion is a clinical-stage biopharmaceutical company with multiple drug candidates in Phase I clinical trials. No commercial products or revenue currently. As a wholly-owned subsidiary of Bayer AG, the company is funded through Bayer's investment for drug development activities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Vividion Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops first-in-class covalent small molecule therapeutics using a proprietary chemoproteomics platform. The company is advancing three clinical-stage candidates (VVD-214 WRN inhibitor, VVD-037 KEAP1 activator, VVD-642 RAS-PIK3CA inhibitor) for oncology indications and earlier-stage immunology programs, targeting protein classes previously considered undruggable.

Product overview

Vividion Therapeutics is a clinical-stage biopharmaceutical company developing a diversified pipeline of first-in-class small molecule therapeutics for previously undruggable disease targets in oncology and immunology. The company's core offerings include three clinical-stage programs: VVD-037 (KEAP1 Activator) for NRF2-activated solid tumors, VVD-214 (WRN Inhibitor) for MSI-high cancers, and VVD-642 (RAS-PIK3CA Inhibitor) for RAS-driven cancers. These programs are enabled by Vividion's proprietary chemoproteomics discovery platform, which combines a covalent fragment library (50,000+ molecules), high-throughput mass spectrometry screening, and an integrated data portal to identify and develop highly selective small molecule drugs against challenging protein targets.

Differentiator

Problem solved

Functional benefit

Products and services

• VVD-214 (WRN Inhibitor) An investigational oral covalent inhibitor of Werner helicase (WRN) designed to treat MSI-high solid tumors including colorectal, endometrial, ovarian, and gastric cancers by exploiting the dependency of MSI-high cancer cells on WRN-mediated DNA repair while sparing healthy tissue.
• VVD-037 (KEAP1 Activator) A first-in-class small molecule KEAP1 activator that allosterically enhances KEAP1's ability to degrade NRF2, designed to treat solid tumors with NRF2 pathway activation including non-small cell lung cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma.
• VVD-642 (RAS-PIK3CA Inhibitor) A small molecule inhibitor that blocks RAS-dependent PIK3CA oncogenic signaling by specifically inhibiting the interaction between RAS and PIK3CA without disrupting homeostatic signaling, designed for use in combination with MAPK pathway inhibitors for RAS-driven cancers.
• Multiple Undisclosed Immunology Programs Early-stage immunology programs leveraging Vividion's covalent-first chemoproteomics platform to identify and characterize functional sites on proteins linked to immune diseases with high unmet need.

Quantifiable outcome

• VVD-214 showed robust tumor regression in multiple patient-derived xenograft mouse models of MSI-high colorectal cancer in preclinical studies
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Arvinas: Clinical-stage company pioneering targeted protein degradation using covalent ligand technology (PROTACs), overlapping with Vividion's covalent chemistry expertise and undruggable target focus. Applicable to similar oncology and immunology indications.
• Kymera Therapeutics: Clinical-stage biotech using targeted protein degradation (degraders/covalent modality) to drug previously undruggable targets in oncology and immunology. Comparable in modality innovation and target-class ambition.

Direct peers

• Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapeutics, including a WRN inhibitor program (similar mechanism to Vividion's VVD-214) for MSI-high cancers. Most direct mechanistic competitor in the WRN inhibitor space.
• Scorpion Therapeutics: Clinical-stage oncology company developing precision small molecule therapies for previously undruggable targets, including programs against cancer-relevant proteins. Closely comparable in stage, modality, and target class philosophy to Vividion.
• Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway, directly relevant to Vividion's RAS-PIK3CA program (VVD-642). Competes in RAS-driven cancer space with similar target patient populations.
• Tango Therapeutics: Clinical-stage biotechnology company developing synthetic lethality-based precision oncology medicines targeting cancer-specific vulnerabilities, overlapping with Vividion's chemoproteomics-driven target identification approach.
• Foghorn Therapeutics: Clinical-stage oncology company developing medicines targeting the chromatin regulatory system using a proprietary platform, paralleling Vividion's platform-based approach to previously undruggable cancer targets.
• Relay Therapeutics: Clinical-stage precision oncology company using motion-based protein design to drug previously undruggable targets, including RAS-driven cancers. Comparable in targeting intractable oncology targets with a platform-enabled approach.

Broad incumbents

• Blueprint Medicines: Established precision oncology company with multiple approved and clinical-stage kinase-targeted therapies, including covalent inhibitors. Comparable target class and indication overlap, with greater commercial maturity.
• Mirati Therapeutics: Commercial-stage precision oncology company (acquired by Bristol-Myers Squibb) with approved KRAS inhibitors (Krazati), directly competitive with Vividion's RAS pathway program (VVD-642). Provides established commercial benchmark in the space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vividion-therapeutics
• Xx.com/vividionrx

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds5 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vividion Therapeutics